Acta Neuropathologica

, 117:169 | Cite as

Olfactory bulb α-synucleinopathy has high specificity and sensitivity for Lewy body disorders

  • Thomas G. Beach
  • Charles L. WhiteIII
  • Christa L. Hladik
  • Marwan N. Sabbagh
  • Donald J. Connor
  • Holly A. Shill
  • Lucia I. Sue
  • Jeanne Sasse
  • Jyothi Bachalakuri
  • Jonette Henry-Watson
  • Haru Akiyama
  • Charles H. Adler
  • The Arizona Parkinson’s Disease Consortium
Original Paper

Abstract

Involvement of the olfactory bulb by Lewy-type α-synucleinopathy (LTS) is known to occur at an early stage of Parkinson’s disease (PD) and Lewy body disorders and is therefore of potential usefulness diagnostically. An accurate estimate of the specificity and sensitivity of this change has not previously been available. We performed immunohistochemical α-synuclein staining of the olfactory bulb in 328 deceased individuals. All cases had received an initial neuropathological examination that included α-synuclein immunohistochemical staining on sections from brainstem, limbic and neocortical regions, but excluded olfactory bulb. These cases had been classified based on their clinical characteristics and brain regional distribution and density of LTS, as PD, dementia with Lewy bodies (DLB), Alzheimer’s disease with LTS (ADLS), Alzheimer’s disease without LTS (ADNLS), incidental Lewy body disease (ILBD) and elderly control subjects. The numbers of cases found to be positive and negative, respectively, for olfactory bulb LTS were: PD 55/3; DLB 34/1; ADLS 37/5; ADNLS 19/84; ILBD 14/7; elderly control subjects 5/64. The sensitivities and specificities were, respectively: 95 and 91% for PD versus elderly control; 97 and 91% for DLB versus elderly control; 88 and 91% for ADLS versus elderly control; 88 and 81% for ADLS versus ADNLS; 67 and 91% for ILBD versus elderly control. Olfactory bulb synucleinopathy density scores correlated significantly with synucleinopathy scores in all other brain regions (Spearman R values between 0.46 and 0.78) as well as with scores on the Mini-Mental State Examination and Part 3 of the Unified Parkinson’s Disease Rating Scale (Spearman R −0.27, 0.35, respectively). It is concluded that olfactory bulb LTS accurately predicts the presence of LTS in other brain regions. It is suggested that olfactory bulb biopsy be considered to confirm the diagnosis in PD subjects being assessed for surgical therapy.

Keywords

Parkinson’s disease, surgery Deep brain stimulation Gene therapy Transplantation Dementia with Lewy bodies, diagnosis, therapy, clinical trial α-Synuclein, Lewy bodies, incidental Lewy body disease Biopsy Olfactory bulb 

References

  1. 1.
    Adler CH (2005) Nonmotor complications in Parkinson’s disease. Mov Disord 20 Suppl 11:S23–S29PubMedCrossRefGoogle Scholar
  2. 2.
    Beach TG, Adler CH, Sue LI, Peirce JB, Bachalakuri J, sing-Hernandez JE, Lue LF, Caviness JN, Connor DJ, Sabbagh MN, Walker DG (2008) Reduced striatal tyrosine hydroxylase in incidental Lewy body disease. Acta Neuropathol 115:445–451PubMedCrossRefGoogle Scholar
  3. 3.
    Beach TG, Sue LI, Walker DG, Roher AE, Lue L, Vedders L, Connor DJ, Sabbagh MN, Rogers J (2007) The Sun Health Research Institute Brain Donation Program: description and experience, 1987–2007. Cell Tissue BankGoogle Scholar
  4. 4.
    Beach TG, Tago H, Nagai T, Kimura H, McGeer PL, McGeer EG (1987) Perfusion-fixation of the human brain for immunohistochemistry: comparison with immersion-fixation. J Neurosci Methods 19:183–192PubMedCrossRefGoogle Scholar
  5. 5.
    Bloch A, Probst A, Bissig H, Adams H, Tolnay M (2006) Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol 32:284–295PubMedCrossRefGoogle Scholar
  6. 6.
    Braak H, Bohl JR, Muller CM, Rub U, de Vos RA, Del TK (2006) Stanley Fahn Lecture 2005: the staging procedure for the inclusion body pathology associated with sporadic Parkinson’s disease reconsidered. Mov Disord 21:2042–2051PubMedCrossRefGoogle Scholar
  7. 7.
    Braak H, Del Tredici K, Bratzke H, Hamm-Clement J, Sandmann-Keil D, Rub U (2002) Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson’s disease (preclinical and clinical stages). J Neurol 249 Suppl 3:1–5CrossRefGoogle Scholar
  8. 8.
    Cornford ME, Chang L, Miller BL (1995) The neuropathology of Parkinsonism: an overview. Brain Cogn 28:321–341PubMedCrossRefGoogle Scholar
  9. 9.
    Daniel SE, Hawkes CH (1992) Preliminary diagnosis of Parkinson’s disease by olfactory bulb pathology. Lancet 340:186PubMedCrossRefGoogle Scholar
  10. 10.
    Doty RL, Deems DA, Stellar S (1988) Olfactory dysfunction in Parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 38:1237–1244PubMedGoogle Scholar
  11. 11.
    Fujishiro H, Tsuboi Y, Lin WL, Uchikado H, Dickson DW (2008) Co-localization of tau and alpha-synuclein in the olfactory bulb in Alzheimer’s disease with amygdala Lewy bodies. Acta Neuropathol 116:17–24PubMedCrossRefGoogle Scholar
  12. 12.
    Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, Goldberg MS, Shen J, Takio K, Iwatsubo T (2002) Alpha-Synuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol 4:160–164PubMedCrossRefGoogle Scholar
  13. 13.
    Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33–39PubMedCrossRefGoogle Scholar
  14. 14.
    Gibb WR (1992) Neuropathology of Parkinson’s disease and related syndromes. Neurol Clin 10:361–376PubMedGoogle Scholar
  15. 15.
    Gill CE, Konrad PE, Davis TL, Charles D (2007) Deep brain stimulation for Parkinson’s disease: the Vanderbilt University Medical Center experience, 1998–2004. Tenn Med 100:45–47PubMedGoogle Scholar
  16. 16.
    Harbaugh RE (1985) Brain biopsy in Alzheimer’s disease: surgical technique and indications. Bull Clin Neurosci 50:39–43PubMedGoogle Scholar
  17. 17.
    Hawkes C (2006) Olfaction in neurodegenerative disorder. Adv Otorhinolaryngol 63:133–151PubMedGoogle Scholar
  18. 18.
    Hladik CL, White CL (2003) Comparison of digestive enzyme and formic acid pretreatment for optimal immunohistochemical demonstration of alpha-synuclein-immunoreactive cerebral cortical Lewy neurites. J Neuropathol Exp Neurol 62:554Google Scholar
  19. 19.
    Hubbard PS, Esiri MM, Reading M, McShane R, Nagy Z (2007) Alpha-synuclein pathology in the olfactory pathways of dementia patients. J Anat 211:117–124PubMedCrossRefGoogle Scholar
  20. 20.
    Hughes AJ, Daniel SE, Kilford L, Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 55:181–184PubMedCrossRefGoogle Scholar
  21. 21.
    Hughes AJ, Daniel SE, Lees AJ (2001) Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease. Neurology 57:1497–1499PubMedGoogle Scholar
  22. 22.
    Katzenschlager R, Lees AJ (2004) Olfaction and Parkinson’s syndromes: its role in differential diagnosis. Curr Opin Neurol 17:417–423PubMedCrossRefGoogle Scholar
  23. 23.
    Kovacs T, Papp MI, Cairns NJ, Khan MN, Lantos PL (2003) Olfactory bulb in multiple system atrophy. Mov Disord 18:938–942PubMedCrossRefGoogle Scholar
  24. 24.
    Kranick SM, Duda JE (2008) Olfactory dysfunction in Parkinson’s disease. Neurosignals 16:35–40PubMedCrossRefGoogle Scholar
  25. 25.
    Lang AE, Houeto JL, Krack P, Kubu C, Lyons KE, Moro E, Ondo W, Pahwa R, Poewe W, Troster AI, Uitti R, Voon V (2006) Deep brain stimulation: preoperative issues. Mov Disord 21 Suppl 14:S171–S196PubMedCrossRefGoogle Scholar
  26. 26.
    Linazasoro G (2008) Olfaction testing in PD: risky conclusions. Mov Disord 23:1060PubMedCrossRefGoogle Scholar
  27. 27.
    Litvan I, MacIntyre A, Goetz CG, Wenning GK, Jellinger K, Verny M, Bartko JJ, Jankovic J, McKee A, Brandel JP, Chaudhuri KR, Lai EC, D’Olhaberriague L, Pearce RK, Agid Y (1998) Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol 55:969–978PubMedCrossRefGoogle Scholar
  28. 28.
    Mahendra B (1984) Some ethical issues in dementia research. J Med Ethics 10:29–31PubMedCrossRefGoogle Scholar
  29. 29.
    Master Z, McLeod M, Mendez I (2007) Benefits, risks and ethical considerations in translation of stem cell research to clinical applications in Parkinson’s disease. J Med Ethics 33:169–173PubMedCrossRefGoogle Scholar
  30. 30.
    McKeith IG, Dickson DW, Lowe J, Emre M, O’Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del ST, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, Kosaka K, Lee VM, Lees A, Litvan I, Londos E, Lopez OL, Minoshima S, Mizuno Y, Molina JA, Mukaetova-Ladinska EB, Pasquier F, Perry RH, Schulz JB, Trojanowski JQ, Yamada M (2005) Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65:1863–1872PubMedCrossRefGoogle Scholar
  31. 31.
    McKeith IG, Galasko D, Kosaka K, Perry EK, Dickson DW, Hansen LA, Salmon DP, Lowe J, Mirra SS, Byrne EJ, Lennox G, Quinn NP, Edwardson JA, Ince PG, Bergeron C, Burns A, Miller BL, Lovestone S, Collerton D, Jansen EN, Ballard C, de Vos RA, Wilcock GK, Jellinger KA, Perry RH (1996) Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology 47:1113–1124PubMedGoogle Scholar
  32. 32.
    McKinnon JH, Demaerschalk BM, Caviness JN, Wellik KE, Adler CH, Wingerchuk DM (2007) Sniffing out Parkinson disease: can olfactory testing differentiate Parkinsonian disorders? Neurologist 13:382–385PubMedGoogle Scholar
  33. 33.
    Obeso JA, Rodriguez MC, Gorospe A, Guridi J, Alvarez L, Macias R (1997) Surgical treatment of Parkinson’s disease. Baillieres Clin Neurol 6:125–145PubMedGoogle Scholar
  34. 34.
    Paluzzi A, Belli A, Bain P, Liu X, Aziz TM (2006) Operative and hardware complications of deep brain stimulation for movement disorders. Br J Neurosurg 20:290–295PubMedCrossRefGoogle Scholar
  35. 35.
    Pearce RK, Hawkes CH, Daniel SE (1995) The anterior olfactory nucleus in Parkinson’s disease. Mov Disord 10:283–287PubMedCrossRefGoogle Scholar
  36. 36.
    Rodriguez RL, Fernandez HH, Haq I, Okun MS (2007) Pearls in patient selection for deep brain stimulation. Neurologist 13:253–260PubMedCrossRefGoogle Scholar
  37. 37.
    Seijo FJ, varez-Vega MA, Gutierrez JC, Fdez-Glez F, Lozano B (2007) Complications in subthalamic nucleus stimulation surgery for treatment of Parkinson’s disease. Review of 272 procedures. Acta Neurochir (Wien) 149:867–875CrossRefGoogle Scholar
  38. 38.
    Subramanian T (2001) Cell transplantation for the treatment of Parkinson’s disease. Semin Neurol 21:103–115PubMedCrossRefGoogle Scholar
  39. 39.
    Tir M, Devos D, Blond S, Touzet G, Reyns N, Duhamel A, Waucquier N, Cottencin O, Dujardin K, Debailleul AM, Cassim F, Destee A, Defebvre L, Krystkowiak P (2007) Exhaustive, one-year follow-up of subthalamic nucleus deep brain stimulation in a large, single-center cohort of parkinsonian patients. NeurosurgeryGoogle Scholar
  40. 40.
    The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer’s Disease (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer’s disease. Neurobiol Aging 18:S1–S2Google Scholar

Copyright information

© Springer-Verlag 2008

Authors and Affiliations

  • Thomas G. Beach
    • 1
  • Charles L. WhiteIII
    • 2
  • Christa L. Hladik
    • 2
  • Marwan N. Sabbagh
    • 1
  • Donald J. Connor
    • 1
  • Holly A. Shill
    • 1
  • Lucia I. Sue
    • 1
  • Jeanne Sasse
    • 1
  • Jyothi Bachalakuri
    • 1
  • Jonette Henry-Watson
    • 1
  • Haru Akiyama
    • 3
  • Charles H. Adler
    • 4
  • The Arizona Parkinson’s Disease Consortium
  1. 1.Sun Health Research InstituteSun CityUSA
  2. 2.University of Texas Southwestern Medical CenterDallasUSA
  3. 3.Tokyo Institute of PsychiatryTokyoJapan
  4. 4.Mayo ClinicScottsdaleUSA

Personalised recommendations